Clinical and pathologic factors predicting reclassification in active surveillance cohorts

by Pablo S. Sierra, Shivashankar Damodaran, David Jarrard

Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.

by William E Jarrard, Adam Schultz, Tyler Etheridge, Shivashankar Damodaran, Glenn O Allen, David Jarrard, Bing Yang
Published 2019-01-01

Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence.

by Jennifer Wagner, Nathan Damaschke, Bing Yang, Matthew Truong, Chad Guenther, Johnathon McCormick, Wei Huang, David Jarrard
Published 2015-01-01

Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes

by Shivashankar Damodaran, Nathan Damaschke, Joseph Gawdzik, Bing Yang, Cedric Shi, Glenn O. Allen, Wei Huang, John Denu, David Jarrard
Published 2017-12-01